INAB IN8BIO INC

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

IN8bio to Present at the TD Cowen 45th Annual Health Care Conference

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- . (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company focused on innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will be presenting at the TD Cowen 45th  Annual Health Care Conference on Monday, March 3, 2025, at 10:30 a.m. ET.

A live webcast and replay will be available under "Events and Presentations" in the News & Presentations section of the IN8bio website at .

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program INB-400 is in a Phase 2 trial in GBM. Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit .

Investor & Corporate Contact

Glenn Schulman, PharmD, MPH

IN8bio, Inc.

203.494.7411

Media Contact

Kimberly Ha

KKH Advisors

917.291.5744



EN
26/02/2025

Underlying

INABIN8BIO INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IN8BIO INC

 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T C...

IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager (TCE) for Autoimmune Disease at ASGCT 2025 Powerful B cell Targeting: INB-619 precisely targets and eliminates B cells from lupus patient samples, including harmful IgG1 and IgM antibodies, demonstrating potential as a treatment for autoimmune diseases Innovative Next Generation TCE Platform: INB-619 gamma-delta (γδ) TCE platform not only depletes its target CD19+ B cells, but also significantly expands and activates both key types of γδ T cells (Vδ1+ and Vδ2+), overcoming one of the critical challenges in pa...

May 14, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell ...

IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products Company receives ISCT abstract award for the analytical characterization of its manufactured gamma-delta T cell therapies in the INB-100 trial, which has demonstrated durable, relapse-free survival in AML patients. IN8bio’s proprietary gamma-delta T cell manufacturing platform generates robust and reproducible products that are activated and primed for tumor cell killing, migration and immune cell recruitment. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- . (...

May 12, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Reports First Quarter 2025 Financial Results and Recent Busines...

IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights Phase 1 clinical data of INB-100 continues to demonstrate long-term durable remissions, with 100% of treated Acute Myeloid Leukemia (AML) patients remaining relapse-free with median follow-up of 20.1 months as of January 17, 2025, as presented at the 2025 Transplantation & Cellular Therapy (TCT) Meetings On May 1st, 2025, we celebrated the 5th anniversary of the first patient ever treated with a gamma-delta T cell therapy being developed by IN8bio. This older patient with complex AML and multiple genetic a...

May 7, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cel...

IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune diseases, today announced that it will present new clinical and preclinical data from its pipeline of gamma-delta T cell therapies at several upcoming scientific conferences. “The breadth of data we’re presenting at upcoming medical conferences reflects the scientific rigor and clinical potentia...

April 29, 2025 1 EN
 PRESS RELEASE
Free
INAB IN8BIO INC

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T C...

IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 First gamma-delta (γδ) TCE to demonstrate significant γδ T cell expansion and activation, potentially offering an alternative to conventional CD3-based approaches without significant adverse events such as cytokine release syndrome (CRS)INB-600 TCE platform significantly expands both Vδ1+ and Vδ2+ subsets to address the reduced cell counts that have limited earlier γδ TCE therapies in cancer patientsINB-619 (CD19) and INB-633 (CD33) consistently show potent and highly targeted anti-...

April 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch